I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
It is a potent and selective CB2 receptor partial agonist (EC50 = 0.65 nM; maximum inhibition = 44.6%). Binds with high affinity to both human and rat CB2 receptors and displays ~ 1200-fold selectivity over CB1 (Ki values are 3.92 and 4772 nM for human recombinant CB2 and CB1 receptors respectively). Produces potent antihyperalgesic effects in several rodent models of pain.
LaBuda CJ, et al. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.Eur J Pharmacol.,2005,527(1-3), 172-4.
Valenzano KJ, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.Neuropharmacology.,2005,48(5), 658-72.
Hazard Statements: H301
Toxic if swallowed.
Precautionary Statements: P264-P270-P301+P310a-P321-P405-P501a
Wash thoroughly after handling. Do not eat, drink or smoke when using this product. IF SWALLOWED: Specific treatment (see label). Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.